Triple

T2523475
Position Surface form Disambiguated ID Type / Status
Subject CBD E55577 entity
Predicate approvedDrugForm P39643 FINISHED
Object Epidiolex
Epidiolex is a prescription cannabidiol-based medication used to treat certain rare and severe forms of epilepsy.
E275978 NE FINISHED

How this triple was built (5 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Epidiolex | Statement: [CBD, approvedDrugForm, Epidiolex]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Epidiolex
Context triple: [CBD, approvedDrugForm, Epidiolex]
  • A. Anpezan
    Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
  • B. Spinraza
    Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
  • C. Waylivra
    Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
  • D. Darzalex
    Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
  • E. Novafora
    Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Epidiolex
Triple: [CBD, approvedDrugForm, Epidiolex]
Generated description
Epidiolex is a prescription cannabidiol-based medication used to treat certain rare and severe forms of epilepsy.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Epidiolex
Target entity description: Epidiolex is a prescription cannabidiol-based medication used to treat certain rare and severe forms of epilepsy.
  • A. Anpezan
    Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
  • B. Spinraza
    Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
  • C. Waylivra
    Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
  • D. Darzalex
    Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
  • E. Novafora
    Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
  • F. None of above. chosen
PD Predicate disambiguation gpt-5-mini-2025-08-07
Target predicate: approvedDrugForm
Context triple: [CBD, approvedDrugForm, Epidiolex]
  • A. hasDosageForm
    Indicates the specific physical form or presentation in which a drug or medicinal product is supplied or administered (e.g., tablet, injection, cream).
  • B. FDAApprovalType
    Indicates the specific regulatory pathway or category under which a product has been approved by the U.S. Food and Drug Administration.
  • C. isExtendedReleaseFormulationOf
    Indicates that one pharmaceutical formulation is an extended-release version of another, designed to release the active ingredient more slowly over time.
  • D. isProdrugOf
    Indicates that one substance is a precursor form that is metabolized in the body to produce the active form of another substance.
  • E. isFirstDrugApprovedFor
    Indicates that a drug is the earliest or original medication approved for treating a particular condition, disease, or indication.
  • F. None of above. chosen

Provenance (7 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69ab49e4749c8190813311efd1630f1b completed March 6, 2026, 9:40 p.m.
NER Named-entity recognition batch_69abd23a0a548190b44393e0f823f7a9 completed March 7, 2026, 7:22 a.m.
NED1 Entity disambiguation (via context triple) batch_69af2ba96a0c819091efd6d4ccf95ea5 completed March 9, 2026, 8:20 p.m.
NEDg Description generation batch_69af508c28f48190afc4aa1bc3c9adf3 completed March 9, 2026, 10:58 p.m.
NED2 Entity disambiguation (via description) batch_69af5155f85081908dd4a1859d0f7907 completed March 9, 2026, 11:01 p.m.
PD Predicate disambiguation batch_69abd0c144b0819092f32a13c1d127e5 completed March 7, 2026, 7:16 a.m.
PDg Predicate description generation batch_69abd1487e0c8190b90dcf30586ad4cd completed March 7, 2026, 7:18 a.m.
Created at: March 6, 2026, 9:46 p.m.